colestipol / Generic mfg. - LARVOL DELTA

Beyond AMA-Negative PBC: Unmasking Oligogenic Cholestasis in an Adult With Indeterminate Biliary Injury (ACG 2026) - "The patient took Actigall for over a decade, with symptomatic and biochemical benefit, but stopped in 2021 due to access barriers. Subsequently, her LFTs steadily rose and were unresponsive to colestipol...Extensive laboratory work-up Figure: Table 2. Cholestasis genetic panel results"

Clinical • Cardiovascular • Cholestasis • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Portal Hypertension • Primary Biliary Cholangitis • Pruritus

Successful Spinal Anesthesia for Cesarean Delivery in a Patient With Severe Cholestatic Liver Disease, Coagulopathy, and Morphine Allergy (ASA 2026) - "She had pruritus treated with ursodiol and colestipol and was taking aspirin; allergies included morphine. Spinal anesthesia used bupivacaine, fentanyl 20 mcg, and clonidine 300 mcg, avoiding intrathecal morphine. Delivery was uneventful; QBL was 660 mL."

Clinical • Allergy • Autoimmune Hepatitis • Cardiovascular • Cholestasis • Gynecology • Hematological Disorders • Hepatology • Hypertension • Immunology • Inflammation • Pruritus

Severe Hypertriglyceridemia Unmasked by Bile Acid Sequestrant Therapy in A Patient with A CREB3L3 Variant Unknown Significance (ENDO 2026) - "After dietary counseling, discontinuation of colestipol, and initiation of fenofibrate, triglycerides improved to the 500-600 mg/dL range. This case demonstrates severe hypertriglyceridemia unmasked by colestipol in a patient with a CREB3L3 variant of uncertain significance, underscoring the importance of considering genetic susceptibility in patients with unexplained or medication-sensitive hypertriglyceridemia."

Clinical • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Severe Hypertriglyceridemia

Comparison chart: Some non-statin lipid-lowering drugs. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Drugs for hypercholesterolemia. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dyslipidemia • Metabolic Disorders

DETECTING SAFETY SIGNALS OF BILE ACID THERAPEUTICS: A FDA FAERS-BASED PHARMACOVIGILANCE STUDY (ISPOR 2026) - "Chenodiol (Ctexli), a synthetic bile acid, recently repurposed to treat cerebrotendinous xanthomatosis (CTX) in adults, has a limited well-defined real world safety data...Safety signals were evaluated using established criteria based on the reporting odds ratio (ROR) and proportional reporting ratio (PRR), each with 95% confidence intervals, along with the chi-square statistic (χ²) and p-values, with signals defined as ROR and PRR > 2, a lower 95% CI bound > 1, χ² ≥ 3, and p < 0.005. Disproportionality analysis identified potential safety signals associated with chenodiol, cholestyramine, colesevelam, and colestipol... Chenodiol's recent approval for cerebrotendinous xanthomatosis exemplifies how existing medications can be re-evaluated for new indications, and other therapeutic options. Integrating real-world safety data from post-marketing surveillance is crucial to supporting these repurposing efforts and ensuring patient safety."

Adverse events • Clinical

Association of pharmacotherapy with all-cause mortality among patients with irritable bowel syndrome. (PubMed, Commun Med (Lond)) - "These findings raise concerns regarding the safety of antidepressants and mu receptor agonists in IBS treatment and underscore the need for cautious prescribing and further research."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Anti-CD19 Chimeric Antigen Receptor T-cell Therapy for Patients with Non-Hodgkin's Lymphoma and Concurrent Autoimmune Disease (TCT-ASTCT-CIBMTR 2026) - "9 pts (37.5%) remained on AID tx at apheresis, including hydroxychloroquine (HCQ) (n=4), sulfasalazine/mesalamine (n=2), and 1 each of prednisone, colestipol, sulfasalazine, and apremilast. In this study of CART for NHL we found no difference in clinical outcomes for pts with AID; we therefore propose that AID should not preclude the use of CART. The majority of pts were able to taper off AID tx prior to CART and HCQ was able to be safely continued throughout CART collection with no effect on efficacy. Our study also highlights the potential effect of CD19 directed CART on pt's AID given the majority of patients remained off AID tx for an extended time post-CART."

CAR T-Cell Therapy • Clinical • Ankylosing Spondylitis • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Dermatology • Dermatomyositis • Gastroenterology • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Myasthenia Gravis • Myositis • Non-Hodgkin’s Lymphoma • Psoriasis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

The impact of bile acid sequestrants on octreotide absorption. (PubMed, J Pharm Sci) - "Our in vivo data suggests that using the BAS, colestipol, did not have a significant impact on peptide absorption though. These results highlight the important role of BAPMM on bioaccessible drug concentration, as well as membrane permeation."

Journal • Gastrointestinal Disorder • CDH1

Efficacy and Safety of Adjunctive Bile Acid Sequestrant Therapy for Thyrotoxicosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Thyroid) - "MEDLINE, Embase, Web of Science, and Cochrane databases were searched from March 1971 to September 2025 for randomized controlled trials (RCTs) assessing adult non-critically ill patients with hyperthyroidism treated with standard therapy (thionamides and beta-blocker) plus adjunctive bile acid sequestrants (cholestyramine or colestipol) versus standard therapy alone. However, due to considerable heterogeneity and low quality of evidence, our results should be interpreted with caution. Larger, high-quality RCTs are needed to strengthen the evidence regarding the efficacy of adjunctive bile acid sequestrant therapy."

Journal • Retrospective data • Endocrine Disorders • Grave’s Disease

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease (ASH 2025) - "methotrexate, hydroxychloroquine (HCQ),azathioprine); 9 required biologic/targeted DMARD (ex. adalimumab, etanercept, risankizumab,infliximab, rituximab).DMARDs were weaned prior to CART however 9 pts (37.5%) remained on AID tx at the time of cellcollection, including HCQ (n=4), sulfasalazine/mesalamine (n=2), and 1 each of prednisone, colestipol,sulfasalazine, and apremilast... In this single center study of pts receiving CART for NHL we found no difference in responserates nor survival outcomes in pts with or without AID and therefore propose that AID should notpreclude the use of CART. Lower severity of ICANS was seen in AID pts, though additional study withlarger cohorts is required. The majority of pts were able to taper off AID tx prior to CART, while HCQ wasable to be safely continued throughout CART collection with no apparent effect on CART efficacy."

CAR T-Cell Therapy • Clinical • Ankylosing Spondylitis • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Dermatology • Dermatomyositis • Gastroenterology • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Myasthenia Gravis • Myositis • Non-Hodgkin’s Lymphoma • Psoriasis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Lipid-Lowering Therapy Is Underutilized Across LDL-C Levels in Autoimmune Disease Compared to Diabetes: A Nationwide Analysis (AHA 2025) - "Statins included atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin. Non-statin therapies included icosapent ethyl, colesevelam, alirocumab, evolocumab, Bempedoic acid, cholestyramine, Inclisiran, colestipol, ezetimibe, gemfibrozil, omega-3 acid, fenofibrate...Non-statin lipid-lowering therapy use was significantly lower in autoimmune patients compared to those with diabetes across all LDL-C tertiles, with the largest differences observed at LDL <70 mg/dL (6.19% vs 10.24%, p<0.0001) and 70–99 mg/dL (4.05% vs 7.06%, p<0.0001).ConclusionDespite comparable ASCVD risk, patients with autoimmune disease are significantly less likely to receive statins or non-statin lipid-lowering therapy than those with DM across LDL-C levels. These findings show a need for improved cardiovascular prevention in this high-risk population."

Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Hepatology • Immunology • Inflammatory Arthritis • Lupus • Metabolic Disorders • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus

Diffuse Eosinophilic Gastrointestinal Disease Secondary to Strongyloides stercoralis (ACG 2025) - "Despite treatment with Reglan for concerns of esophageal dysmotility and Carafate, he lost 65lbs and intermittently required parenteral nutrition...Patient was placed on prednisone and colestipol, and although his weight stabilized, his diarrhea persisted with intermittent nocturnal incontinence...Colonic biopsy revealing extensive background eosinophilia1b. Evidence of rare parasitic microorganisms within crypts"

Eosinophilia • Gastroenterology • Gastrointestinal Disorder • Infectious Disease

A Macroscopic Mystery: An Atypical Presentation of Microscopic Colitis (ACG 2025) - "Budesonide and cholestyramine offered limited relief.In the setting of persistent symptoms and fecal calprotectin elevation to 2410mcg/gm, vedolizumab was initiated...Despite use of vedolizumab, colestipol 4gm, budesonide 9mg, and anti-diarrheals, the patient remained symptomatic with multiple bowel movements per day.The patient was subsequently changed to infliximab...This case underscores the importance of recognizing atypical features of collagenous colitis and maintaining a high index of suspicion for overlapping or evolving diagnoses, particularly in those who fail conventional therapy. This case also elevates the discussion of microscopic colitis as part of a spectrum of chronic inflammatory bowel diseases.Figure: Index colonoscopy with mucosal inflammation and possible pseudomembranes"

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mucositis

Management of Type 2 Amiodarone-Induced Thyrotoxicosis With a Combination of Low-Dose Prednisone and Bile Acid Resin to Attain Euthyroid State. (PubMed, AACE Endocrinol Diabetes) - "The patients were treated with a combination of moderately low-dose prednisone (25 mg/d and 20 mg/d, respectively) and bile acid binding resins (colestipol 3 g/d and cholestyramine 12 g/d, respectively). This combination treatment effectively managed thyrotoxicosis while minimizing steroid exposure. In patients with type 2 AIT and relative contraindication to high-dose steroids, a combination of moderately low-dose prednisone and bile acid binding resins offers a safe and effective treatment alternative."

Journal • Atrial Fibrillation • Cardiovascular • Endocrine Disorders • Hepatitis B • Infectious Disease • Inflammation • Osteoporosis • Rheumatology

Efficacy and Safety of Adjunctive Bile Acid Sequestrant Therapy for Thyrotoxicosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (ATA 2025) - "This meta-analysis assesses the potential utility of BAS adjunctive therapy to lower serum iodothyronine levels more rapidly than standard therapy alone. We systematically searched across MEDLINE, Embase, Web of Science and Cochrane databases from database inception to January 2025, to retrieve randomized controlled trials (RCTs) comparing the reduction of serum free T4 and total T3 levels in non-critically ill adult patients with hyperthyroidism receiving standard therapy (thionamides and beta-blocker) with adjunctive BAS (cholestyramine or colestipol) versus standard therapy alone. The use of adjunctive BAS compared to standard hyperthyroidism therapy alone showed statistical significance on the reduction of total T3 and free T4 at the mark of 4 weeks. Overall, there were minimal adverse effects noted by the addition of BAS. This study is limited by the small patient sample size of the trials and larger RCTs are needed to strengthen the evidence regarding the efficacy..."

Retrospective data • Review • Endocrine Disorders • Grave’s Disease

Fecal and Clinical Profiles of Dogs With Chronic Enteropathies Treated With Bile Acid Sequestrants for 5-47 Months: A Retrospective Case Series. (PubMed, J Vet Intern Med) - "Treatment with BAS as adjunctive treatment potentially may benefit some dogs with nonresponsive or partially immunosuppressive-responsive enteropathy or CE dogs requiring high doses of corticosteroids."

Journal • Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders

Management Of Type II Amiodarone-induced Thyrotoxicosis With Low Dose Prednisone And Colestipol, A Bile Acid Binding Resin. (ENDO 2025) - "He was treated with amiodarone 6 months ago, but with onset of thyrotoxicosis, he was switched to dronedarone. Colestipol, a bile acid binding resin has dual mechanism of action in the management of thyrotoxicosis associated with thyroiditis. Bile-salt sequestrants bind thyroid hormones in the intestine and thereby increase their fecal excretion. Studies have also indicated that colestipol significantly reduces the enterohepatic circulation of amiodarone and lowers the serum levels of amiodarone."

Late-breaking abstract • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Endocrine Disorders • Heart Failure • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Ophthalmology • Thyroid Eye Disease

Update of safety profile of bile acid sequestrants: A real-world pharmacovigilance study of the FDA adverse event reporting system. (PubMed, PLoS One) - "This large-scale FAERS study updates the safety profiles of BASs, highlighting distinct risk patterns and delayed complications. The findings support personalized monitoring strategies that consider both drug-specific characteristics and temporal AE patterns."

Adverse events • Journal • Real-world evidence • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Musculoskeletal Diseases • Musculoskeletal Pain • Pain

TRANSORAL OUTLET REDUCTION FOR TREATMENT OF REFRACTORY BILE ACID ESOPHAGITIS AFTER ROUX-EN-Y GASTRIC BYPASS AND BRAUN ENTEROENTEROSTOMY (SSAT 2025) - "Initial management involves treatment with bile acid sequestrants such as ursodeoxycholic acid and PPI therapy...She was initially trialed on PPI and bile acid sequestrants including cholestyramine and colestipol with mild relief of her symptoms...TORe has gained increasing recognition for treatment of weight recurrence in patients with dilated GJ outlet after RYGB. To our knowledge, this is the first case report of the use of TORe for treatment of refractory bile acid reflux in a patient with RYGB and dilated GJ outlet."

Bariatric surgery • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Pain • Peptic Ulcer

TRANSORAL OUTLET REDUCTION FOR TREATMENT OF REFRACTORY BILE ACID ESOPHAGITIS AFTER ROUX-EN-Y GASTRIC BYPASS AND BRAUN ENTEROENTEROSTOMY (DDW 2025) - "Initial management involves treatment with bile acid sequestrants such as ursodeoxycholic acid and PPI therapy...She was initially trialed on PPI and bile acid sequestrants including cholestyramine and colestipol with mild relief of her symptoms...TORe has gained increasing recognition for treatment of weight recurrence in patients with dilated GJ outlet after RYGB. To our knowledge, this is the first case report of the use of TORe for treatment of refractory bile acid reflux in a patient with RYGB and dilated GJ outlet."

Bariatric surgery • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Pain • Peptic Ulcer

Comparative Effectiveness of Bile Acid Sequestrants and Antibiotics in the Management of Acute Pouchitis: A Matched Cohort Study from the United States. (PubMed, Dig Dis Sci) - "Using real-world evidence regarding treatment of pouchitis compared to standard antibiotic therapy, BAS monotherapy was not inferior for initial treatment response and significantly prolonged time to recurrent pouchitis."

HEOR • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Comparison chart: Safety of drugs for IBS in pregnancy and lactation. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Gastrointestinal Disorder

Drugs for irritable bowel syndrome. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Comparison chart: Some drugs for irritable bowel syndrome with diarrhea (IBS-D). (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Gastrointestinal Disorder